Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

70 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Technically unresectable recurrent oral cancers: Is NACT the answer?
Patil VM, Joshi A, Noronha V, Karpe A, Ramaswamy A, Dhumal S, Juvekar S, Arya S, Mahajan A, Chaturvedi P, Pai P, D'Cruz A, Prabhash K. Patil VM, et al. Among authors: karpe a. Oral Oncol. 2016 May;56:e12-4. doi: 10.1016/j.oraloncology.2016.03.015. Epub 2016 Mar 31. Oral Oncol. 2016. PMID: 27050928 No abstract available.
Metronomic palliative chemotherapy in maxillary sinus tumor.
Patil VM, Noronh V, Joshi A, Karpe A, Talreja V, Chandrasekharan A, Dhumal S, Prabhash K. Patil VM, et al. Among authors: karpe a. South Asian J Cancer. 2016 Apr-Jun;5(2):56-8. doi: 10.4103/2278-330X.181626. South Asian J Cancer. 2016. PMID: 27275447 Free PMC article.
Drug-sensitive FGFR3 mutations in lung adenocarcinoma.
Chandrani P, Prabhash K, Prasad R, Sethunath V, Ranjan M, Iyer P, Aich J, Dhamne H, Iyer DN, Upadhyay P, Mohanty B, Chandna P, Kumar R, Joshi A, Noronha V, Patil V, Ramaswamy A, Karpe A, Thorat R, Chaudhari P, Ingle A, Choughule A, Dutt A. Chandrani P, et al. Among authors: karpe a. Ann Oncol. 2017 Mar 1;28(3):597-603. doi: 10.1093/annonc/mdw636. Ann Oncol. 2017. PMID: 27998968 Free PMC article.
Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma.
Patil VM, Noronha V, Joshi A, Choughule AB, Bhattacharjee A, Kumar R, Goud S, More S, Ramaswamy A, Karpe A, Pande N, Chandrasekharan A, Goel A, Talreja V, Mahajan A, Janu A, Purandare N, Prabhash K. Patil VM, et al. Among authors: karpe a. ESMO Open. 2017 Apr 27;2(1):e000168. doi: 10.1136/esmoopen-2017-000168. eCollection 2017. ESMO Open. 2017. PMID: 28761735 Free PMC article.
Impact of exon 19 versus exon 21 EGFR-activating mutation on outcomes with upfront pemetrexed-carboplatin chemotherapy.
Noronha V, Patil V, Joshi A, Chougule A, Bhattacharjee A, Kumar R, More S, Goud S, Karpe A, Ramaswamy A, Pande N, Chandrasekharan A, Goel A, Talreja V, Mahajan A, Janu A, Purandare N, Prabhash K. Noronha V, et al. Among authors: karpe a. Ecancermedicalscience. 2017 Oct 24;11:776. doi: 10.3332/ecancer.2017.776. eCollection 2017. Ecancermedicalscience. 2017. PMID: 29104613 Free PMC article.
Development and validation of a predictive score, for identifying poor eastern cooperative oncology group performance status (performance status 3-4) advanced nonsmall cell lung cancer patients who are likely to benefit from tyrosine kinase inhibitors.
Joshi A, Bhattacharjee A, Noronha V, Patil VM, Karpe A, Kadam N, Solanki L, Prabhash K. Joshi A, et al. Among authors: karpe a. Indian J Cancer. 2017 Jan-Mar;54(1):127-131. doi: 10.4103/ijc.IJC_162_17. Indian J Cancer. 2017. PMID: 29199675 Free article.
Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation?
Joshi A, Noronha V, Patil VM, Chougule A, Bhattacharjee A, Kumar R, Goud S, More S, Ramaswamy A, Karpe A, Pande N, Chandrasekharan A, Goel A, Talreja V, Mahajan A, Janu A, Purandare N, Prabhash K. Joshi A, et al. Among authors: karpe a. Chemother Res Pract. 2017;2017:8196434. doi: 10.1155/2017/8196434. Epub 2017 Oct 23. Chemother Res Pract. 2017. PMID: 29201462 Free PMC article.
70 results